PHILADELPHIA, Dec. 6 (UPI) -- Three U.S. health institutions say they've joined to evaluate a potential vaccine designed to prevent transmission of malaria from mosquitoes to humans.
The PATH Malaria Vaccine Initiative, the National Institute of Allergy and Infectious Diseases and the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research will collaborate to conduct a Phase 1 clinical trial in healthy adults to assess the safety and effectiveness of the vaccine, a PATH release said Tuesday.